Literature DB >> 25177612

Comparison of Point of Care (POC) Testing of Glucose by B Braun Glucometer and Hemocue Glucose 201+ Analyser Versus Centralised Testing in Neonatal Intensive Care Unit (NICU).

Sudha Reddy V R1, Sumathi M E2, Beere Gowda Y C3, Mohamed Suhail S4.   

Abstract

BACKGROUND: Neonatal hypoglycemia is the most common carbohydrate metabolic disturbance seen in case of neonates and especially in preterm neonates. Accurate and rapid determination of hypoglycemia and its prompt treatment is of utmost importance to decrease morbidity and mortality of neonates. AIMS: To estimate blood glucose in neonates and test the efficacy of HemoCue Glucose 201+ analyser and B Braun Glucometer by comparing with centralised laboratory testing. To compare the blood glucose in capillary and venous blood samples of neonates. SETTINGS AND
DESIGN: Hospital setting; Comparative Study Materials and
Methods: After obtaining informed consent, all neonates admitted to Neonatal Intensive Care Unit (NICU) were screened for blood sugar. Capillary and venous blood glucose was estimated employing HemoCue Glucose 201+ analyser and B Braun Glucometer. Simultaneously, the same venous sample was collected in fluoride tube and sent to central clinical biochemistry laboratory for glucose estimation. When anaemia or polycythemia was clinically suspected the same venous sample was sent for estimation of Hematocrit (Hct). STATISTICAL ANALYSIS: Comparison of blood glucose concentration of B Braun glucometer, HemoCue Glucose 201+ analyser and centralis/ed plasma glucose levels was done by using students test. All the statistical analysis were done using software SPSS 6 version.
RESULTS: Mean values of blood glucose (100.2 + 48.4) with B Braun glucometer was significantly higher (p=0.003) when compared to plasma glucose values (76.95 + 45.99) estimated in central laboratory and HemoCue glucose 201+ analyser (82.9 + 51.4). HemoCue glucose 201+ analyser did not show significant difference (p=0.463) with central laboratory testing. There was no significant difference between the capillary and venous sample estimated in both the instruments. Estimation with HemoCue glucose 201+ analyser correlated well with central laboratory testing in neonates with blood glucose <55mg/dl,
CONCLUSION: We conclude that HemoCue glucose 201+ analyser appears to be a suitable point of care (POC) blood glucose measurement device in neonates on both capillary and venous blood samples, as it showed a good correlation with central laboratory values without significant interference from Hct.

Entities:  

Keywords:  B Braun glucometer; Blood glucose; HemoCue glucose 201+ analyser; Point of care testing

Year:  2014        PMID: 25177612      PMCID: PMC4149118          DOI: 10.7860/JCDR/2014/8666.4538

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Performance of Precision G blood glucose analyzer with a new test strip G2b on neonatal samples.

Authors:  Burcu Meric; Nazife Kilicaslan; Kagan Kerman; Dilsat Ozkan; Umran Kurun; Nejat Aksu; Mehmet Ozsoz
Journal:  Clin Chem       Date:  2002-01       Impact factor: 8.327

2.  Capillary versus venous bedside blood glucose estimations.

Authors:  R Boyd; B Leigh; P Stuart
Journal:  Emerg Med J       Date:  2005-03       Impact factor: 2.740

3.  Evaluation of the impact of hematocrit and other interference on the accuracy of hospital-based glucose meters.

Authors:  Brad S Karon; Laurie Griesmann; Renee Scott; Sandra C Bryant; Jeffrey A Dubois; Terry L Shirey; Steven Presti; Paula J Santrach
Journal:  Diabetes Technol Ther       Date:  2008-04       Impact factor: 6.118

4.  Point of care estimation of blood glucose in neonates.

Authors:  Sushma Nangia
Journal:  Indian Pediatr       Date:  2012-08       Impact factor: 1.411

5.  Can one point-of-care glucose meter be used for all pediatric and adult hospital patients? Evaluation of three meters, including recently modified test strips.

Authors:  Janet V Warner; Joyce Y Wu; Nita Buckingham; Donald S A McLeod; Barbara Mottram; Andrew C Carter
Journal:  Diabetes Technol Ther       Date:  2011-01       Impact factor: 6.118

Review 6.  Postnatal glucose homeostasis in late-preterm and term infants.

Authors:  David H Adamkin
Journal:  Pediatrics       Date:  2011-02-28       Impact factor: 7.124

7.  Comparison of the accuracy of the HemoCue glucose analyzer with the Yellow Springs Instrument glucose oxidase analyzer, particularly in hypoglycemia.

Authors:  Alexander D M Stork; Hans Kemperman; D Willem Erkelens; Thiemo F Veneman
Journal:  Eur J Endocrinol       Date:  2005-08       Impact factor: 6.664

8.  Reliability assessment of glucose measurement by HemoCue analyser in a neonatal intensive care unit.

Authors:  Carlo Bellini; Giovanni Serra; Domenico Risso; Massimo Mazzella; Eugenio Bonioli
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

9.  Evaluation of "point of care" devices in the measurement of low blood glucose in neonatal practice.

Authors:  H T Ho; W K Y Yeung; B W Y Young
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-07       Impact factor: 5.747

10.  Screening for hypoglycemia at the bedside in the neonatal intensive care unit (NICU) with the Abbott PCx glucose meter.

Authors:  Cynthia Balion; Vijaylaxmi Grey; Afisi Ismaila; Susan Blatz; Wendy Seidlitz
Journal:  BMC Pediatr       Date:  2006-11-03       Impact factor: 2.125

View more
  2 in total

1.  Effect of a Whey Protein Supplement on Preservation of Fat Free Mass in Overweight and Obese Individuals on an Energy Restricted Very Low Caloric Diet.

Authors:  Anne Ellegaard Larsen; Bo Martin Bibby; Mette Hansen
Journal:  Nutrients       Date:  2018-12-04       Impact factor: 5.717

2.  Improving physical activity, pain and function in patients waiting for hip and knee arthroplasty by combining targeted exercise training with behaviour change counselling: study protocol for a randomised controlled trial.

Authors:  Jane O'Brien; Kyra Hamilton; Andrew Williams; James Fell; Jonathan Mulford; Michael Cheney; Sam Wu; Marie-Louise Bird
Journal:  Trials       Date:  2018-08-07       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.